ZEVRA THERAPEUTICS, INC. Quarterly General and Administrative Expense in USD from Q1 2014 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Summary
Zevra Therapeutics, Inc. quarterly/annual General and Administrative Expense history and growth rate from Q1 2014 to Q4 2022.
  • Zevra Therapeutics, Inc. General and Administrative Expense for the quarter ending December 31, 2022 was $5.08M, a 98.6% increase year-over-year.
  • Zevra Therapeutics, Inc. General and Administrative Expense for the twelve months ending December 31, 2022 was $15.3M, a 76.3% increase year-over-year.
  • Zevra Therapeutics, Inc. annual General and Administrative Expense for 2022 was $15.3M, a 76.3% increase from 2021.
  • Zevra Therapeutics, Inc. annual General and Administrative Expense for 2021 was $8.7M, a 9.85% increase from 2020.
  • Zevra Therapeutics, Inc. annual General and Administrative Expense for 2020 was $7.92M, a 26.8% decline from 2019.
General and Administrative Expense, Trailing 12 Months (USD)
General and Administrative Expense, Quarterly (USD)
General and Administrative Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 $15.3M $5.08M +$2.52M +98.6% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-07
Q3 2022 $12.8M $3.97M +$2.03M +104% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $10.8M $3.56M +$1.25M +54.4% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-12
Q1 2022 $9.54M $2.73M +$842K +44.5% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-12
Q4 2021 $8.7M $2.56M +$28K +1.11% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-07
Q3 2021 $8.67M $1.95M +$519K +36.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $8.15M $2.31M +$586K +34.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 $7.57M $1.89M -$353K -15.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $7.92M $2.53M +$1.15M +83.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 $6.77M $1.43M -$2.18M -60.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $8.95M $1.72M -$1.27M -42.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 $10.2M $2.25M -$593K -20.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 $10.8M $1.38M -$1.59M -53.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 $12.4M $3.61M +$621K +20.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-30
Q2 2019 $11.8M $2.99M -$431K -12.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 $12.2M $2.84M -$294K -9.39% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q4 2018 $12.5M $2.96M +$350K +13.4% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-28
Q3 2018 $12.2M $2.99M -$327K -9.85% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $12.5M $3.42M -$154K -4.31% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 $12.6M $3.13M -$134K -4.1% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q4 2017 $12.8M $2.61M -$259K -9.02% Oct 1, 2017 Dec 31, 2017 10-K 2018-03-30
Q3 2017 $13M $3.32M +$215K +6.93% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 $12.8M $3.57M -$713K -16.6% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-10
Q1 2017 $13.5M $3.27M -$470K -12.6% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-11
Q4 2016 $14M $2.87M +$307K +12% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-30
Q3 2016 $13.7M $3.1M +$952K +44.2% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-30
Q2 2016 $12.7M $4.29M +$1.1M +34.5% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-30
Q1 2016 $11.6M $3.74M +$2.76M +282% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-30
Q4 2015 $8.88M $2.57M +$989K +62.7% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-10
Q3 2015 $7.89M $2.15M +$1.07M +98.2% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-10
Q2 2015 $6.83M $3.19M +$1.86M +140% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-10
Q1 2015 $4.97M $977K +$443K +83% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-10
Q4 2014 $4.53M $1.58M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-16
Q3 2014 $1.09M Jul 1, 2014 Sep 30, 2014 10-K 2016-03-16
Q2 2014 $1.33M Apr 1, 2014 Jun 30, 2014 10-K 2016-03-16
Q1 2014 $534K Jan 1, 2014 Mar 31, 2014 10-K 2016-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.